TY - JOUR
T1 - Screening for Lipid Disorders in Children and Adolescents
T2 - US Preventive Services Task Force Recommendation Statement
AU - Barry, Michael J.
AU - Nicholson, Wanda K.
AU - Silverstein, Michael
AU - Chelmow, David
AU - Coker, Tumaini Rucker
AU - Davis, Esa M.
AU - Donahue, Katrina E.
AU - Jaén, Carlos Roberto
AU - Li, Li
AU - Ogedegbe, Gbenga
AU - Rao, Goutham
AU - Ruiz, John M.
AU - Stevermer, James
AU - Tsevat, Joel
AU - Underwood, Sandra Millon
N1 - Publisher Copyright: © 2023 American Medical Association. All rights reserved.
PY - 2023/7/18
Y1 - 2023/7/18
N2 - Importance: Familial hypercholesterolemia and multifactorial dyslipidemia are 2 conditions that cause abnormally high lipid levels in children, which can lead to premature cardiovascular events (eg, myocardial infarction and stroke) and death in adulthood. Objective: The US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for lipid disorders in asymptomatic children and adolescents. Population: Asymptomatic children and adolescents 20 years or younger without a known diagnosis of a lipid disorder. Evidence Assessment: The USPSTF concludes that the current evidence is insufficient and the balance of benefits and harms for screening for lipid disorders in asymptomatic children and adolescents 20 years or younger cannot be determined. Recommendation: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents 20 years or younger. (I statement).
AB - Importance: Familial hypercholesterolemia and multifactorial dyslipidemia are 2 conditions that cause abnormally high lipid levels in children, which can lead to premature cardiovascular events (eg, myocardial infarction and stroke) and death in adulthood. Objective: The US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for lipid disorders in asymptomatic children and adolescents. Population: Asymptomatic children and adolescents 20 years or younger without a known diagnosis of a lipid disorder. Evidence Assessment: The USPSTF concludes that the current evidence is insufficient and the balance of benefits and harms for screening for lipid disorders in asymptomatic children and adolescents 20 years or younger cannot be determined. Recommendation: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents 20 years or younger. (I statement).
UR - http://www.scopus.com/inward/record.url?scp=85164988757&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85164988757&partnerID=8YFLogxK
U2 - 10.1001/jama.2023.11330
DO - 10.1001/jama.2023.11330
M3 - Review article
C2 - 37462699
SN - 0098-7484
VL - 330
SP - 253
EP - 260
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 3
ER -